OKYO Pharma Limited NOTICE OF GENERAL MEETING AND CIRCULAR PUBLICATION (3880V)
05 April 2023 - 4:00PM
UK Regulatory
TIDMOKYO
RNS Number : 3880V
OKYO Pharma Limited
05 April 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM ANY JURISDICTION
IN WHICH THE SAME WOULD BE A VIOLATION OF THE LAWS OF SUCH
JURISDICTION. NEITHER THIS ANNOUNCEMENT, NOR ANYTHING CONTAINED
HEREIN, SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION
WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.
NOTICE OF GENERAL MEETING AND PUBLICATION OF CIRCULAR
London and New York, NY, 5 April 2023 - OKYO Pharma Limited
(Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an
ophthalmology-focused bio-pharmaceutical company which is
developing OK-101 to treat dry eye disease to address the
significant unmet need in this multi-billion-dollar market,
announces that, further to its announcement on 4 April 2023, it has
today posted a circular (the "Circular") to shareholders which
contains further details regarding the proposed cancellation of its
ordinary shares of no par value each ("Ordinary Shares") from
listing on the standard segment of the Official List of the
Financial Conduct Authority and trading on the main market for
listed securities of London Stock Exchange plc and associated
timetable, together with proposals to be put to shareholders at a
general meeting of the Company to be held at the offices of Orrick,
Herrington & Sutcliffe (UK) LLP at 107 Cheapside, London EC2V
6DN, United Kingdom at 12.00 midday on 3 May 2023 (the "General
Meeting"), including, inter alia, to consolidate every 65 existing
Ordinary Shares into one new ordinary share of no par value
(thereby matching its current American Depositary Share ratio). The
Circular will shortly be posted to the Company's website at:
https://okyopharma.com/investors/corporate-governance/corporate-documents/
Enquiries:
OKYO Pharma Gary S. Jacob, Chief Executive
Limited Officer +44 (0)20 7495 2379
Investor Relations Paul Spencer +44 (0)20 7495 2379
Robert Emmet, Optiva Securities
Broker Limited +44 (0)20 3981 4173
Notes for Editors:
About OKYO
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences
company admitted to listing on NASDAQ and on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the main market for listed securities of London Stock
Exchange plc. OKYO is focusing on the discovery and development of
novel molecules to treat inflammatory dry eye diseases and chronic
pain. For further information, please visit www.okyopharma.com
.
About OK-101
OK-101 is a lipid conjugated chemerin peptide antagonist of the
ChemR23 G-protein coupled receptor which is typically found on
immune cells of the eye responsible for the inflammatory response.
OK-101 was developed using a membrane-anchored-peptide (MAP)
technology to produce a novel long-acting drug candidate for
treating dry eye disease. OK-101 has been shown to produce
anti-inflammatory and pain-reducing activities in mouse models of
dry eye disease and corneal neuropathic pain; and is designed to
combat washout through the inclusion of the lipid 'anchor'
contained in the candidate drug molecule to enhance the residence
time of OK-101 within the ocular environment.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAXLLELSDEFA
(END) Dow Jones Newswires
April 05, 2023 02:00 ET (06:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2023 to Apr 2024